Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced that it has expanded its
intellectual property portfolio in medical robotics with the
issuance of 30 additional U.S. patents since January 2011. Hansen
Medical also shares rights to more than 250 issued U.S. patents
relating to medical robotics through licensing arrangement with
third parties.
Certain of the patents provide additional coverage for Hansen
Medical's Magellan™ Robotic System, which is designed to treat a
variety of peripheral vascular diseases and is currently being
commercialized in the United States and the European Union. Several
of the patents also provide additional coverage for Hansen
Medical's Sensei® X Robotic Catheter System, while others provide
innovative solutions for potential future advancements to its
robotic technologies.
"Patent protection is very important in our industry," said
Bruce J Barclay, Hansen Medical president and chief executive
officer. "Significant value at Hansen Medical lies in the
intellectual property assets we have developed for use in our
products and that can be used across a number of platforms outside
of our core markets. We continue to work diligently to build patent
protection covering the innovative work being performed by our
talented engineers and scientists at the company."
Specifically, the 30 additional patents received by Hansen
Medical are U.S. Patent No. 7,867,241, titled Flexible Instrument;
7,905,828, Flexible Instrument; 7,918,861, Flexible Instrument;
7,947,050, Surgical Instrument Coupling Mechanism; 7,972,298,
Robotic Catheter System; 7,974,681, Robotic Catheter System;
7,901,399, Interchangeable Surgical Instrument; 7,922,693,
Apparatus Systems and Methods for Flushing Gas from a Catheter of a
Robotic Catheter System; 7,931,586, Flexible Instrument; 7,935,059,
System and Method for 3-D Imaging; 7,947,051, Surgical Instrument
Coupling Mechanism; 7,955,316, Coaxial Catheter System; 7,959,557,
Robotic Medical Instrument System; 7,963,288, Robotic Catheter
System; 7,976,539, System and Method for Denaturing and Fixing
Collagenous Tissue; 8,005,537, Robotically Controlled Intravascular
Tissue Injection System; 8,007,511, Surgical Instrument Design;
8,021,326, Instrument Driver for Robotic Catheter System;
8,041,413, Systems and Methods for Three-Dimensional Ultrasound
Mapping; 8,052,621, Method of Sensing Forces on a Working
Instrument; 8,052,636, Robotic Catheter System and Methods;
8,083,691, Apparatus and Method for Sensing Force; 8,092,397,
Apparatus for Measuring Distal Forces on a Working Instrument;
8,108,069, Robotic Catheter System and Methods; 8,114,097, Flexible
Instrument; 8,146,874, Mounting Support Assembly for Suspending a
Medical Instrument Driver Above an Operating Table; 8,160,690,
System and Method for Determining Electrode-Tissue Contact Based on
Amplitude Modulation of Sensed Signal; 8,172,747, Balloon
Visualization for Traversing a Tissue Wall; 8,187,229, Coaxial
Catheter System; and 8,190,238, Robotic Catheter System and
Methods.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the
global leader in intravascular robotics, developing products and
technology designed to enable the accurate positioning,
manipulation and control of catheters and catheter-based
technologies. The Company's Magellan™ Robotic System, NorthStar™
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei® X Robotic
Catheter System and Artisan Control Catheter are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the Lynx® Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter were cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment
of cardiac arrhythmias, including AF, have not been
established.
Additional information can be found at
www.hansenmedical.com.
Forward-Looking Statements This press
release contains forward-looking statements regarding, among other
things, statements relating to goals, plans, objectives, milestones
and future events. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words "plan," "expects," "potential," "believes," "goal,"
"estimate," "anticipates," and similar words. These statements are
based on the current estimates and assumptions of our management as
of the date of this press release and are subject to risks,
uncertainties, changes in circumstances and other factors that may
cause actual results to differ materially from the information
expressed or implied by forward-looking statements made in this
press release. Examples of such statements include statements about
the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for
the sales cycle for newly introduced products; the rate of adoption
of our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to maintain our remedial
actions over previously reported material weaknesses in internal
controls over financial reporting; our ability to manage expenses
and cash flow, and obtain additional financing; and other risks
more fully described in the "Risk Factors" section of our Quarterly
Report on Form 10-Q for the quarter ended June 30, 2012 filed with
the SEC on August 9, 2012 and the risks discussed in our other
reports filed with the SEC. Given these uncertainties, you should
not place undue reliance on the forward-looking statements in this
press release. We undertake no obligation to revise or update
information herein to reflect events or circumstances in the
future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact John Capodanno
212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024